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973Atrial Remodeling Following Catheter-Based
Renal Denervation Occurs in a Blood Pressure–
and Heart Rate–Independent MannerABSTRACTOBJECTIVES This study sought to investigate left atrial (LA) remodeling in relation to blood pressure (BP) and heart
rate (HR) after renal sympathetic denervation (RDN).
BACKGROUND In addition to reducing BP and HR in certain patients with hypertension, RDN can decrease left
ventricular (LV) mass and ameliorate LV diastolic dysfunction.
METHODS Before and 6 months after RDN, BP, HR, LV mass, left atrial volume index (LAVI), diastolic function
(echocardiography), and premature atrial contractions (PAC) (Holter electrocardiogram) were assessed in 66 patients
with resistant hypertension.
RESULTS RDN reduced ofﬁce BP by 21.6  3.0/10.1  2.0 mm Hg (p < 0.001), and HR by 8.0  1.3 beats/min (p <
0.001). At baseline, LA size correlated with LV mass, diastolic function, and pro-brain natriuretic peptide, but not with BP
or HR. Six months after RDN, LAVI was reduced by 4.0  0.7 ml/kg/m2 (p < 0.001). LA size decrease was stronger when
LAVI at baseline was higher. In contrast, the decrease in LAVI was not dependent on LV mass or diastolic function (E/E0 or
E/A) at baseline. Furthermore, LAVI decreased without relation to decrease in systolic BP or HR. Additionally, occurrence
of PAC (median of >153 PAC/24 h) was reduced (to 68 PAC/24 h) by RDN, independently of changes in LA size.
CONCLUSIONS In patients with resistant hypertension, LA volume and occurrence of PAC decreased 6 months after
RDN. This decrease was independent of BP and HR at baseline or the reduction in BP and HR reached by renal dener-
vation. These data suggest that there is a direct, partly BP-independent effect of RDN on cardiac remodeling and
occurrence of premature atrial contractions. (J Am Coll Cardiol Intv 2015;8:972–80) © 2015 by the American College of
Cardiology Foundation.SEE PAGE 981C ardiac pressure overload results in cardiacremodeling including myocardial hypertro-phy, diastolic dysfunction, and left atrial
(LA) enlargement. Renal sympathetic denervation
(RDN) represents a novel technique in the treatment
of uncontrolled hypertension, documented to reduce
ofﬁce and ambulatory blood pressure (BP) as well as
central sympathetic activity in certain patients with
uncontrolled hypertension (1). In the randomized,
sham-controlled SYMPLICITY HTN-3 study (Renal
Denervation in Patients With Uncontrolled Hyperten-
sion), the primary safety endpoint was met; however,
the primary efﬁcacy endpoint (reduction in ofﬁce sys-
tolic blood pressure between the groups) was not met
except in the pre-deﬁned subgroup of Caucasian
patients (2). Recently published post-hoc analyses of
SYMPLICITY HTN-3 data revealed several potential
confounding factors, including weakness in proce-
dural performance, which may partially explain the
lower than anticipated response to RDN (3,4). Further
research on the effects of RDN on BP and other organsystems is, therefore, warranted given the not fully
unambiguous effects in different patient populations
and different technical approaches (2).Next to its effects on BP, RDN can lower heart rate
(HR) in patients with resistant hypertension (5). RDN
can also attenuate LV hypertrophy (6), and we pre-
viously showed that LV mass regression by RDN oc-
curs independently of BP and HR changes (7); thus,
potential BP-independent effects on cardiovascular
pathology of RDN have been hypothesized (8). Fur-
thermore, several BP-independent effects of RDN
have been described, potentially expanding the range
of therapeutic interventions on the sympathetic ner-
vous systems (9–12). There is a direct correlation be-
tween myocardial hypertrophy and LA size (13). The
latter, if enlarged >34 ml/m2, is predictive of heart
failure (14), ischemic stroke, and death (15). There are
reports of LA enlargement independent of blood
pressure (16), although a correlation between LA size
ABBR EV I A T I ON S
AND ACRONYMS
ABPM = ambulatory blood
pressure monitoring
BP = blood pressure
HR = heart rate
LAVI = left atrial volume index
LVMI = left ventricular mass
index
PAC = premature atrial
contractions
proBNP = pro-brain natriuretic
peptide
RDN = renal sympathetic
denervation
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974and hypertension is assumed (17). LA elec-
trical and structural remodeling leads to
rhythm disorders such as atrial ectopic beats
and atrial ﬁbrillation (AF) (18). The effect
of RDN on LA remodeling assessed using
echocardiography is hitherto unknown. In
the current investigation, we aimed to
assess LA remodeling following RDN in
relation to BP, HR, and parameters of LV
remodeling.METHODS
PATIENT SELECTION. This current study
was approved by the institutional medicalethics committee (No. 67/11) in accordance with the
declaration of Helsinki. Patients (n ¼ 66) scheduled
for RDN for treatment of resistant hypertension
(deﬁned as ofﬁce systolic blood pressure [SBP] $140
mm Hg) were prospectively included using a pre-
speciﬁed analysis protocol (NCT00664638,
NCT00888433, and NCT01888315). Patients were in
sinus rhythm and were not experiencing secondary
causes of hypertension, systolic heart failure (ejec-
tion fraction <50%) or severe renal dysfunction
(estimated glomerular ﬁltration rate <45 ml/min as
measured by cystatin C). Data on this patient popu-
lation have been reported earlier (7).
BP AND HR, DOCUMENTATION OF PREMATURE
ATRIAL CONTRACTIONS. Ofﬁce BP readings were
taken in a seated position with an automatic oscillo-
metric Omron HEM-705 monitor (Omron Healthcare,
Vernon Hills, Illinois) after 5 min of rest according to
the Standard Joint National Committee VII Guidelines
16. At baseline, BP was measured at each arm, and the
arm with the higher BP was used for all subsequent
readings. Averages of the triplicate measures were
calculated and used for analysis. Ambulatory BP
monitoring was performed to exclude pseudo resis-
tant hypertension (mean 24 h SBP <130 mm Hg) (1).
HR was obtained from a 12-lead electrocardiogram.
The 24-h Holter electrocardiograms were used to
determine occurrence of premature atrial contrac-
tions (PAC) (coupling interval #70% of the preceding
RR interval) (Pathﬁnder, Reynolds Medical and
Spacelabs, Snoqualmie, Washington). To distinguish
between ventricular and atrial premature beats, the
parameters width, area under the curve, and slew rate
of the QRS complex were analyzed.
ECHOCARDIOGRAPHY. Transthoracic echocardiog-
raphy was performed by the same operator(M.M.Y.A.S.), who was blinded to BP data and pa-
tient status, on a Vivid E9 (General Electric, Frank-
furt Germany) before and 6 months after RDN. The
investigation included regular 2-dimensional echo-
cardiography, Doppler, and tissue Doppler imaging
according to the guidelines of the American Society
of Echocardiography (19). All studies were read off-
line by an investigator blinded to patient status
(S.H.S.). LA volume was measured in a biplane
fashion in 4- and 2-chamber apical views using a
modiﬁed Simpson’s method and was indexed to
body surface area, which was calculated according to
the Mosteller formula (20), to calculate left atrial
volume index (LAVI). LV mass was calculated from
the end-diastolic diameters of the interventricular
septum, the LV posterior wall, and the LV cavity
using the Devereux formula (21), and LV mass was
indexed to height to the 2.7th power. LV diastolic
function was assessed by using tissue Doppler-
derived measurements of the E0 septal and E0
lateral wave (peak early diastolic septal and lateral
mitral annular velocities), and calculation of the ratio
of the maximum E-wave velocity and the mean E0-
wave. Diastolic dysfunction was deﬁned according to
current guidelines (22).
RDN PROCEDURE. Following renal artery angiog-
raphy, RDN was performed bilaterally using the Flex
catheter system (Medtronic, Minneapolis, Minne-
sota), as previously reported (23). In both renal ar-
teries, circumferential radio-frequency ablations at a
maximum power of 8W lasting 2 min each were per-
formed. All RDN procedures were performed by
experienced operators (>15 RDN procedures/
interventionist).
STATISTICAL ANALYSIS. Data are presented as mean
 SEM. Data were analyzed for normal distribution
using the Kolmogorov-Smirnov test. Normally
distributed parameters were compared between
baseline and 6-month follow-up using a paired
Student t test, or a Wilcoxon matched pair test if not
normally distributed. Tertiles of LAVI, LVMI, E/E0,
SBP, HR, and PAC were built to investigate the rela-
tion between parameters. Pearson’s correlation ana-
lyses were used to calculate the correlation between
the change in BP/HR/ambulatory blood pressure
monitoring (ABPM) and the change in echocardio-
graphic parameters. Repeated measures analysis of
variance was performed with testing for interaction of
tertiles and time when comparing the change in 3
tertiles. Differences were considered signiﬁcant if p
was <0.05. SPSS version 20.0 (IBM, Armonk, New
York) was used for statistical calculations.




(6 Months) p Value
SBP, mm Hg 172.9  3.0 151.3  3.2 <0.001
DBP, mm Hg 92.5  2.3 85.5  1.6 <0.001
Heart rate, beats/min 67.7  1.3 60.5  1.2 <0.001
Systolic ABPM, mm Hg
(n ¼ 50)
155.2  2.5 141.2  2.7 <0.001
Diastolic ABPM, mm Hg
(n ¼ 50)
82.5  1.6 79.0  2.1 0.047
LVMI, g/m2.7 61.5  2.0 53.4  1.5 <0.001
LAVI, ml/m2 34.4  1.1 30.3  0.9 <0.001
Emax, cm/s 66.9  2.6 72.9  2.1 0.013
Deceleration time, ms 252  9 227  6 0.010
E0, ms 6.6  0.27 7.35  0.28 0.011
E/A 0.89  0.05 1.01  0.06 0.002
Values are mean  SD. Data from Schirmer et al. (7).
ABPM ¼ ambulatory blood pressure monitoring; DBP ¼ diastolic blood pressure;
Emax ¼ maximum E-wave velocity; LAVI ¼ left atrial volume index; LVMI ¼ left
ventricular mass index; SBP ¼ systolic blood pressure.
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975RESULTS
BASELINE CHARACTERISTICS. Patients in the treat-
ment group had a mean age of 63.5  1.2 years. A total
of 36 of 66 study patients (54.5%) were male. Average
body mass index was 29.4  0.6 kg/m2. Patients were
on 4.3  0.1 antihypertensive drugs (Table 1).
BP EFFECTS. As previously reported elsewhere (7) in
this patient cohort, BP decreased from 172.9 
3.0/92.5  2.3 mm Hg to 151.3  3.2/85.5  1.6 mm Hg
(p < 0.001 for both), corresponding to a decrease of
21.6  3.0/10.1  2.0 mm Hg. The decrease in BP was
conﬁrmed by ABPM measurements. HR decreased
from 67.7  1.3 beats/min to 60.5  1.2 beats/min
(p < 0.001), an average decrease of 8.0  1.3
beats/min. See also Table 2 for BP and ABPM data.
LA SIZE AT BASELINE. Because of the known LV
hypertrophy in the patient cohort (7), correlation of
LV mass index and LA volume index was assessed at
baseline. Elevated LV mass was correlated with
increased LA volume (r ¼ 0.389, p ¼ 0.002). Similarly,
LAVI correlated with diastolic E/E0 as the measure of
diastolic function (r ¼ 0.335, p ¼ 0.009) and with log
pro-brain natriuretic peptide (BNP) levels in serum
(r ¼ 0.498, p < 0.001). Assessing the relation between
LAVI and hemodynamic parameters at baseline
showed that SBP (also when assessed as ABPM) and
HR were constant throughout the range of LA size,
although there was a trend toward increased LA size
with lower HR (Figure 1).TABLE 1 Baseline Characteristics (n ¼ 66)
Age, yrs 63.5  1.2
Male 36 (55)
BMI, m/kg2 29.4  0.6
BSA, m2 1.99  0.02
Diabetes 23 (35)
Hypercholesterolemia 42 (64)
Current or former smokers 14 (21)
Coronary artery disease 14 (21)
Number of antihypertensive drugs 4.3  0.1
Beta-blocker 59 (89)
Calcium-channel blocker 52 (79)
ACE inhibitor 25 (38)
Angiotensin receptor blocker 36 (55)
Diuretic agent 66 (100)
Renin inhibitor 26 (39)
Alpha blocker 27 (41)
Direct vasodilator 10 (15)
Values are mean  SD or n (%). Data from Schirmer et al. (7)
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; BSA ¼ body
surface area.RENAL DENERVATION-INDUCED DECREASE IN LAVI
DEPENDS ON LA SIZE. Six months after RDN, LA size
assessed as LAVI decreased from 34.4  1.1 ml/m2 to
30.3  0.9 ml/m2, or by 4.0  0.7 ml/m2 (p < 0.001)
(Table 2). When tertiles were deﬁned according to
LAVI at baseline (n ¼ 22 patients each), patients with
the smallest atria (25.5  0.6 ml/m2) depicted un-
changed atrial size, whereas the tertile with the
highest LAVI at baseline (44.1  1.2 ml/m2) showed
the strongest reduction in LA size (from 7.7 1.3 ml/m2
to 36.4  1.7 ml/m2, p < 0.001) (p for interaction of
tertiles <0.001) (Figure 2).
REDUCTION OF LA SIZE OCCURRED INDEPENDENTLY
OF CHANGES IN LV MORPHOLOGY AND FUNCTION.
Next, we investigated whether LAVI decrease differed
according to LV hypertrophy, LV diastolic function,
BP, or HR. LAVI decreased to the same extent in all
tertiles of LVMI at baseline (from 33.5  2.0 ml/m2 to
28.58  1.7 ml/m2 [p ¼ 0.001] in the ﬁrst, from 32.9 
1.7 ml/m2 to 29.5  1.4 ml/m2 [p ¼ 0.019] in the sec-
ond, and from 36.5  1.7 ml/m2 to 33.8  1.8 ml/m2
[p ¼ 0.032] in the third tertile) (p for interaction of
tertiles ¼ 0.461). Reduction of LAVI was similarly
comparable in all tertiles of LVMI reduction (p for
interaction of tertiles ¼ 0.526). LAVI also regressed
comparably in all tertiles of diastolic function (E/E0) at
baseline: from 30.7  2.1 ml/m2 to 28.0  1.8 ml/m2
(p ¼ 0.039) in the ﬁrst, from 32.8.6  1.6 ml/m2 to 27.6
 1.0 ml/m2 (p ¼ 0.001) in the second, and from 39.2 
1.9 ml/m2 to 35.3  1.8 ml/m2 (p ¼ 0.007) in the third
tertile. Again, there was no trend for a change in LAVI
decrease (p ¼ 0.406). In the same way, LAVI
FIGURE 1 Left Ventricular Hypertrophy and Diastolic Function Predict Left Atrial Size
Associations between left atrial volume index (LAVI) and left ventricular mass index (LVMI) (A), diastolic function (E/E0) (B), serum log pro-
brain natriuretic peptide (BNP) levels (C), systolic blood pressure (SBP) (D), and heart rate (HR) (E) at baseline. LAVI correlated with LVMI, E/E0,
and proBNP, but not with SBP or HR. BPM ¼ beats/min.
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976regression was independent of the change of E/A as
another parameter of diastolic function (p for inter-
action of tertiles of E/A at baseline ¼ 0.280). Subse-
quently, change in LA size was evaluated in relationFIGURE 2 Change in LA Volume Index Depends on LA Size
Left-atrial volume index (LAVI) was reduced 6 months after renal sympat
increasing LAVI at baseline showed dependence of the effect on left atrto the decrease in BP and HR achieved by RDN. Across
all tertiles of SBP decrease, LAVI decreased to a
similar extent (from 35.8  2.2 ml/m2 to 32.7  1.9 ml/
m2 [p ¼ 0.031] in the ﬁrst, from 33.4  1.6 ml/m2 tohetic denervation in the whole patient group (A). Analyzing tertiles of
ial (LA) size (B).
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97730.2  1.7 ml/m2 [p ¼ 0.031] in the second, and from
33.7  1.7 ml/m2 to 28.9  1.4 ml/m2 [p < 0.001] in the
third tertile) (p for interaction of tertiles ¼ 0.535). A
correlation analysis of SBP decrease (r ¼ 0.188, p ¼
0.134) conﬁrmed the independency. When analyzing
ABPM data that were completely available at base-
line and follow-up (n ¼ 50), again the decrease of
LAVI was comparable in all tertiles of ABPM
reduction (p for interaction of tertiles ¼ 0.767, r ¼
0.169, p ¼ 0.514 in correlation analysis). Likewise,
LAVI reduction occurred similarly in all tertiles of
HR reduction (from 34.6  2.21 ml/m2 to 31.8  2.1
ml/m2 [p ¼ 0.035] in the ﬁrst, from 35.2  1.6 ml/m2
to 31.4  1.6 ml/m2 [p ¼ 0.010] in the second, and
from 33.6  2.0 ml/m2 to 29.2  1.3 ml/m2 [p ¼
0.005] in the third tertile) (p for interaction ofFIGURE 3 LA Size Regression Is Independent of Left Ventricular Ma
LAVI decreased comparably in all tertiles of LVMI (A) at baseline or E/E0 (B
(D) decrease. Abbreviations as in Figures 1 and 2.tertiles 0.722). Also, there was no correlation be-
tween change in LAVI and change in proBNP
measured in Serum (data not shown). See also
Figure 3 for relations of decrease in LA size with
parameters of LV morphology and function.
A HIGH BURDEN OF ATRIAL ECTOPIC BEATS IS
REDUCED BY RDN. Patients with a history of AF
were excluded from the current study. On Holter
monitor (data available for 40 patients), one-third
(n ¼ 13) of patients had <10 PAC in 24 h. The up-
per tertile with a mean of 153 (interquartile range:
80 to 594) PAC/24 h exhibited a signiﬁcant decrease
in PAC following RDN (decrease to 68 [interquartile
range: 27 to 137] PAC/24 h; p ¼ 0.032). LA size
decreased following RDN in all tertiles of LAss, Diastolic Function, BP, and HR
) at baseline. LAVI decreased similarly in all tertiles of SBP (C) and HR
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978PAC, lacking a correlation of LA morphological and
electrical change (Figure 4).
DISCUSSION
In the current study, LA volume was observed to
decrease following RDN. Although LA volume corre-
lated with LV hypertrophy and diastolic function at
baseline, the decrease following RDN was indepen-
dent of LV changes. It also occurred independently of
BP or HR. A high burden of premature atrial con-
tractions was reduced by RDN.
Reduction of LA size was dependent on LA size
at baseline, with the second and third tertiles of
LA size at baseline showing signiﬁcant reduction
of LAVI following RDN. This is in line with recently
published magnetic resonance data showing a
decrease in LA size (measured as LA surface) only in
those patients with enlarged LA at baseline (24).
Because of the relation of LA size with hard car-
diovascular endpoints such as mortality (18,25),
reducing LA size by RDN allows for speculation
about possible beneﬁcial effects of RDN besides
BP lowering. Experimental studies have recently
also suggested a positive effect of RDN on atrial
remodeling (26).
LA size was shown to correlate with LV
morphology (hypertrophy) at baseline, reﬂecting dataFIGURE 4 High Burden of PAC Decreased, LA Size Decreases Indepe
Dividing the number of premature atrial contractions (PAC) per 24 h int
reduction of a high burden of PAC by renal sympathetic denervation. Th
tertiles of PAC at baseline (B).from the current published data (13). Its change,
however, occurred independently of a change in
cardiac hypertrophy. Similarly, LA enlargement is
known to correlate to diastolic LV dysfunction (27),
because it directly reﬂects increased LV ﬁlling pres-
sure (15) as well as to proBNP serum levels (28). These
ﬁndings are also conﬁrmed by the current data.
However, RDN-induced changes in LV morphology
were independent of change in LV diastolic function,
change in proBNP levels, as well as ofﬁce and ambu-
latory BP measurements, as conﬁrmed by correlation
analyses. The independence of the effects sup-
ports the hypothesis of “pleiotropic” effects of sym-
pathomodulation induced by RDN (7). Because LAVI
and parameters of LV morphology and diastolic
function were correlated at baseline, the indepen-
dence of the changes at follow-up is unexpected.
A lack of statistical power due to small sample size
(n ¼ 22 per tertile) cannot be excluded as a
confounder here.
The herein reported study provides the ﬁrst data of
RDN not only on LA morphology but also on the
occurrence of PAC, potentially representing triggers
for AF (29,30). Because of the role of the autonomic
nervous system in the pathophysiology of AF (31), the
therapeutic potential of RDN in beneﬁcially modi-
fying atrial remodeling and thus, potentially,
arrhythmogenesis has been earlier speculated (32,33).ndently of PAC
o tertiles (plotted as median and interquartile range in A) shows a
e decrease in left atrial (LA) volume index occurred similarly in all
PERSPECTIVES
WHAT IS KNOWN? RDN positively inﬂuences LV mass and
dysfunction.
WHAT IS NEW? The current data show RDN to also reduce LA
size and premature atrial contractions, elucidating effects of the
sympathetic nervous systems on cardiac function.
WHAT IS NEXT? The BP-independent effects of RDN need to
be investigated in further studies.
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979That the lack of association of LA morphological and
functional changes is due to a few patients with a
high burden of PAC at baseline cannot be excluded. In
accordance with this observation in humans, RDN
reduced occurrence of PAC in an animal model for
sleep apnea, which was associated with a reduction in
spontaneous AF episodes (34). This further supports
the concept of a reduction in PAC as 1 important
antiarrhythmic mechanism of RDN by preventing
triggers for AF. Additionally, in a pig model of
AF induced by rapid atrial pacing, RDN reduced
inducible AF duration during programmed atrial sti-
mulation, suggesting that changes in atrial electro-
physiology may be involved in reduced atrial
arrhythmogenesis after RDN. Additionally, RDN
reduced ventricular HR during AF suggesting im-
proved rate control during AF (35). In line with the
current clinical data, the electrophysiological and
morphological effects did not always go in parallel.
Although the current data suggest beneﬁcial atrial
antiarrhythmic effects of RDN, further studies still
need to investigate whether electrophysiological al-
terations are preceded by morphological changes or
occur entirely independently. Another study reported
on reduced AF recurrence following pulmonary vein
isolation with additional RDN (36). First experimental
(10) and clinical (37) data also report positive effects
on unstable ventricular rhythms, that is, electrical
storm (38).
Research in the ﬁeld of RDN is still evolving. Thus,
the sham-controlled SYMPLICITY HTN-3 trial failed
to meet its primary efﬁcacy endpoint. Patient and
operator differences may affect outcomes of the
procedure (3,39). Evidence is growing that BP res-
ponse to RDN varies, and although certain patients
experience a signiﬁcant drop in ofﬁce and ambula-
tory BP following the procedure, others do not.
Recent clinical trials have raised more questions that
warrant further investigation. Further studies willprovide more insights and hopefully answer open
questions, including the potential effects besides BP
lowering.
STUDY LIMITATIONS. The present data are derived
from a relatively small single-center patient popula-
tion. The inﬂuence of other effects, particularly
regression to the mean, on the current data cannot be
excluded. Due to the lack of a control group and/or
a sham procedure, a potential Hawthorne effect
contributing to the outcome cannot be fully excluded.
CONCLUSIONS
Renal denervation reduced LA size and premature
atrial contractions independently of BP and HR
reduction and independently of LV changes. These
data suggest a further direct effect of the sympathetic
nervous systems on cardiac morphology and function.
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